HELP

Cybin Inc. Common Stock

7.71 USD
+0.34
4.61%
At close Updated Jan 9, 12:04 PM EST
1 day
4.61%
5 days
-14.05%
1 month
34.09%
3 months
22.97%
6 months
2.53%
Year to date
-6.88%
1 year
-13.27%
5 years
-92.65%
10 years
-92.65%
 

About: Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Employees: 50

0
Funds holding %
of 7,536 funds
0
Analysts bullish %
of 3 analysts
0
Positive news %
of 3 articles
Price charts implemented using Lightweight Charts™